Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Study finds virus antibodies last at least 12 months

By WANG XIAOYU | CHINA DAILY | Updated: 2021-07-08 09:27
Share
Share - WeChat
A recovering pneumonia patient gives a thumbs-up to medical workers at Wuhan University's Zhongnan Hospital, in early 2020. [GAO XIANG/FOR CHINA DAILY]

Antibodies against the novel coronavirus can last for at least 12 months in more than 70 percent of recovered COVID-19 patients, a study published by Chinese researchers on Tuesday shows.

The finding adds to growing evidence that vaccination, which elicits an immune response in a way similar to how a live virus triggers human bodies to generate antibodies, can "effectively restrict the spread of SARS-CoV-2", the study said.

The study, published online by Nature Communications, was conducted by China National Biotech Group, a Sinopharm subsidiary, and the National Research Center for Translational Medicine at Shanghai Jiao Tong University.

Researchers collected 1,782 convalescent plasma samples from 869 recovered COVID-19 patients in Wuhan, Hubei province, within 12 months of diagnosis, and tested them for the presence and amount of RBDIgG, a type of antibody that indicates the strength of immunity against the virus.

Testing results showed that in nine months, levels of the antibody dropped to 64.3 percent of the initial level when they contracted the virus, and then stabilized into the 12th month.

"It shows that once immune responses against the novel coronavirus are induced in human bodies, antibody levels can be maintained for quite a long time," China National Biotech Group said in an article on its WeChat account on Wednesday.

The study found that the antibody response was significantly stronger in male participants than in their female counterparts in the early stages of infection, but the difference dwindled over time and nearly disappeared in 12 months.

Among participants aged 18 to 55, the older ones developed higher antibody levels, it added.

The company said the study is the longest-running research aimed at examining the persistence of antibody response in recovered COVID-19 patients.

The finding was published as mass vaccination in China proceeds smoothly, with the country stepping up vaccine donations or sales overseas.

As of Tuesday, about 1.3 billion doses of vaccines had been administered nationwide, the National Health Commission said on Wednesday.

China National Biotech Group added that the study will help improve understanding of the immunological memory elicited by the virus, and provide guidance on future research into vaccine-induced immunity and future vaccination policies in China and abroad.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 天天干天天干天天天天天天爽| 欧美午夜春性猛交xxxx| 国产性生交xxxxx免费| av一本久道久久波多野结衣| 日本在线视频播放| 亚洲人成精品久久久久| 狠狠躁夜夜躁人人爽天天天天97 | 韩国出轨的女人| 国产精品泄火熟女| ww在线观视频免费观看w| 日本成人在线网址| 亚洲一区二区三区精品视频| 波多野结衣新婚被邻居| 又爽又黄又无遮挡网站| 韩国在线免费视频| 国产特级毛片aaaaaa高清| 92国产精品午夜福利| 少妇真实被内射视频三四区| 久久久久久亚洲精品中文字幕| 最近的中文字幕视频完整| 亚洲欧美国产五月天综合| 男女边摸边吃奶边做免费观看| 四虎永久在线精品视频免费观看| 黄A无码片内射无码视频| 国产精品久久久久毛片真精品| 亚洲精品福利你懂| 自拍偷自拍亚洲精品偷一| 日本年轻的继坶中文字幕| 四虎国产精品免费久久久| 91黑丝国产线观看免费| 国产精品无码2021在线观看| asspics美女裸体chinese| 性做久久久久久| 久久777国产线看观看精品| 激情综合色综合啪啪开心| 啊轻点灬大ji巴太粗太长了免费| 麻豆女神吴梦梦| 国产精品一级片| 91精品国产手机| 天堂AV无码AV一区二区三区| 一级日本强免费|